Primecap Management Co. CA Sells 873,746 Shares of LivaNova PLC (NASDAQ:LIVN)

Primecap Management Co. CA lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 15.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,754,060 shares of the company’s stock after selling 873,746 shares during the period. Primecap Management Co. CA owned 0.09% of LivaNova worth $220,161,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Cibc World Markets Corp bought a new stake in shares of LivaNova during the 4th quarter valued at $236,000. Vestcor Inc bought a new stake in shares of LivaNova during the 4th quarter valued at $204,000. Swiss National Bank raised its position in shares of LivaNova by 0.7% in the 4th quarter. Swiss National Bank now owns 106,819 shares of the company’s stock worth $4,947,000 after purchasing an additional 700 shares during the last quarter. Ruffer LLP purchased a new position in shares of LivaNova in the 4th quarter worth about $7,982,000. Finally, PNC Financial Services Group Inc. raised its position in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock worth $292,000 after purchasing an additional 1,424 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the subject of several recent analyst reports. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Barclays lowered their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday. Finally, Stifel Nicolaus decreased their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $41.41 on Tuesday. The business has a 50-day simple moving average of $45.88 and a two-hundred day simple moving average of $49.01. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of 98.60 and a beta of 1.10. LivaNova PLC has a fifty-two week low of $36.85 and a fifty-two week high of $64.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.